Pharma IP Summit: Dos and don’ts at the Beijing IP Court
The introduction of expert judges through pilot programmes has been a positive step but refinement is needed, say those close to the action
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: